Ikarian Capital’s iShares Biotechnology ETF IBB Stock Holding History

Ikarian Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-250,000	Closed	-$30.1M	–	163
2019 Q4	$30.1M	Buy	+250,000	New	+$27.9M	4.88%	5

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ikarian Capital's IBB Position: Q3 2025 in Review

Ikarian Capital sold out of iShares Biotechnology ETF (IBB) in Q3 2025, closing a stake of 5,755 shares — an estimated $728K sold.

Ikarian Capital first reported a position in IBB in Q4 2021 and held it in 2 quarters. The position peaked at $3.67M in Q4 2021. 803 funds tracked by Wall St. Rank hold IBB as of Q3 2025.

Ikarian Capital reported no remaining iShares Biotechnology ETF position as of Q3 2025 after selling out during the quarter.
Ikarian Capital sold 5,755 iShares Biotechnology ETF shares in Q3 2025, an estimated $728K.
Ikarian Capital first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 2 quarters.
Ikarian Capital's iShares Biotechnology ETF position peaked at $3.67M in Q4 2021.
803 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.